

FARICIMAB solution for injection (Vabysmo® ▼) for diabetic macular oedema

The Pan Mersey Area Prescribing Committee recommends the prescribing of FARICIMAB solution for injection (Vabysmo® ▼), by specialists only, for diabetic macular oedema in accordance with NICE TA799.

RED

Faricimab is licensed for the treatment of visual impairment due to diabetic macular oedema.¹

[NICE technology appraisal \(TA\) 799](#) (29 June 2022) recommends faricimab as an option for treating diabetic macular oedema only if:

- > the eye has a central retinal thickness of 400 micrometres or more at the start of treatment.²

Faricimab should be prescribed and administered by ophthalmology specialist teams. Prescribing and monitoring should be retained by the specialist.

Costing information

The manufacturer has agreed to provide faricimab according to a commercial arrangement making treatment with faricimab similar in cost to treatment with other suitable treatments. If patients and their clinicians consider faricimab to be one of a range of suitable treatments (including aflibercept and ranibizumab) they should choose the least expensive treatment option, taking account of administration costs, dosage, price per dose and commercial arrangements.²

Based on the NICE Resource Impact Template, NICE estimates that the cost of implementing NICE TA799 is £7,000 per 100,000 population in 2022/23, rising to £11,000 per 100,000 population in 2023/24 and then falling to £3,000 per 100,000 population by 2026/27 when it is assumed that steady state has been reached. This is based on the NHS list price and includes any additional administration costs. The resource impact will be less once the PAS discount is applied.

References

1. Roche Products Limited. Summary of Product Characteristics, [Vabysmo 120 mg/mL solution for injection](#); May 2022. Accessed 28 June 2022.
2. National Institute for Health and Care Excellence. Technology Appraisal 799: [Faricimab for treating diabetic macular oedema](#), 29 June 2022. Accessed 30 June 2022.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.